The technology used to build Chiromics' libraries, invented by the MacMillan Group at Princeton University, employs a chemical synthesis technique referred to as "cascade catalysis." Cascade catalysis allows for the creation of a diverse collection of molecules that are more complex than, and differentiated from, existing pharmaceutical libraries made using linear drug synthesis, all while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis. As a result, where only 15% of proteins have been successfully targeted by existing small molecules, Chiromics' library compounds may reach these and the remaining 85% of targets, many previously thought to be "un-druggable."
"Chiromics' technology and libraries represent a true paradigm shift in pharmaceutical drug discovery," said Samuel D. Waksal, Ph.D., Chairman and Chief Executive Officer of Kadmon. "This platform allows us to identify and produce high-value, pre-clinical candidates against virtually any biologic target with speed and specificity, a feat not possible with other chemistry libraries." Dr. Waksal added, "This agreement is also an example of Kadmon's commitment to accessing and advancing the unsurpassed science and innovation of the academic community here in the United States."
Chiromics' founder David MacMillan, Ph.D., A. Barton Hepburn Professor of Organic Chemistry and Chairman of the Chemistry Department at Princeton University, stated, "Chiromics has developed a technology that can build large, drug-like, broadly diverse collections of molecules with 'accessible complexity,' or novel, three dimensional frameworks which can be readily built using simple catalysis methods. These collections can be made routinely, rapidly and rationally. With its culture of innovation, Kadmon can take full advantage of the potential in this technology by realizing its intended purpose, which is to access the most critical pathways of disease."